B+
Bull case
25%
Probability
Target price
$0.53
Analysis reference price unavailable
Analysis 2025-09-28 · RankAlpha Sentiment AI
DCTH
DelcathFNasdaq / Health Care Equipment & Services
Last Price
Quote time unavailable
AI scenario view
RankAlpha Sentiment AIMost likely
B
Base case
40%
Probability
Target price
$0.30
Analysis reference price unavailable
Analysis 2025-09-28 · RankAlpha Sentiment AI
B-
Bear case
35%
Probability
Target price
$0.15
Analysis reference price unavailable
Analysis 2025-09-28 · RankAlpha Sentiment AI
The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented
AI sentiment snapshot
Latest data as of 2025-09-28
Recent news sentiment (30D)
-
Unavailable
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Weekly research (10D)
+30.0
Positive
Sentiment proxy
0.0
Score
AI commentary
Market tone is cautious-to-negative: investors emphasize financing and commercialization risk for this microcap while a minority cite binary regulatory or adoption catalysts as re-rating opportunities [#10Qp5], [#PR-2024-07]. Trading volume is thin and news-driven moves have dominated price action recently [#MarketData-2025-09].
RankAlpha Sentiment AI - 2025-09-28
Open full AI memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
-eventPotential regulatory developments for chemosaturation systemHigh impact
Any FDA communications, label changes, or new PMA/510(k) activity related to Delcath's chemosaturation / melphalan delivery system could materially move the stock; regulatory timing is uncertain [#10Qp12].
-catalystCommercial adoption / new reimbursementHigh impact
Improved commercial uptake or new reimbursement for targeted liver infusion therapy would support longer-term valuation upside; adoption timelines typically multi-quarter [#PR-2024-07].
2025-12-31catalystLiquidity / financing dilutionHigh impact
Small-cap cash needs may force equity raises that dilute shareholders and depress near-term price; financing risk is high for sub-$1 stocks [#10Qp5].
Recommendation
N/A
No formal recommendation provided.
As of 2025-09-28 • Updated nightlySource: Internal modelMethodology